Paradigm Biopharmaceuticals logo

PAR - Paradigm Biopharmaceuticals Share Price

A$3.49 0.1  1.5%

Last Trade - 5:10am

Sector
Healthcare
Size
Small Cap
Market Cap £346.1m
Enterprise Value £309.0m
Revenue £2.07m
Position in Universe 319th / 1834
Bullish
Bearish
Unlock PAR Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PAR Revenue Unlock PAR Revenue

Net Income

PAR Net Income Unlock PAR Revenue

Normalised EPS

PAR Normalised EPS Unlock PAR Revenue

PE Ratio Range

PAR PE Ratio Range Unlock PAR Revenue

Dividend Yield Range

PAR Dividend Yield Range Unlock PAR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PAR EPS Forecasts Unlock PAR Revenue
Profile Summary

Paradigm Biopharmaceuticals Limited is a biopharmaceutical company focused on repurposing the drug pentosan polysulfate sodium (PPS) for the treatment of inflammation. The Company is engaged in researching and developing therapeutic products for human use. The Company is a drug repurposing company, which seeks to find new uses for old drugs. The Company has commenced the open labelled Phase II clinical trial, investigating the role of the drug PPS in treating traumatic Bone Marrow Lesions. The Company's Rhinosul has properties consisting of both histamine stabilizing and anti-inflammatory properties. The Company focuses on repurposing PPS under ZILOSUL name, as a treatment for bone marrow edema (BME) lesions following traumatic injury.

Directors
Last Annual June 30th, 2019
Last Interim December 31st, 2019
Incorporated May 2, 2014
Public Since August 20, 2015
No. of Shareholders: 4,902
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P/ASX All Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 196,899,099
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PAR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PAR
Upcoming Events for PAR
Similar to PAR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.